Exenatide Lowers HbA1c More Than Oral Antidiabetics or Insulin Glargine

Exenatide Lowers HbA1c More Than Oral Antidiabetics or Insulin Glargine: "Once-Weekly Exenatide Lowers HbA1c More Than Daily Oral Antidiabetics or Insulin Glargine"

Hyperglycemic Crises in Adult Patients With Diabetes: Introduction

Hyperglycemic Crises in Adult Patients With Diabetes: Introduction: "Hyperglycemic Crises in Adult Patients With Diabetes"

7: Old Dog, Old Tricks - Journeys in Survey Research

7: Old Dog, Old Tricks - Journeys in Survey Research: "Old Dog, Old Tricks: Using SPSS Syntax to Avoid the Mouse Trap"

Are we losing the battle against cardiometabolic disease? The case for a paradigm shift in primary prevention.

BioMed Central Full text Are we losing the battle against cardiometabolic disease? The case for a paradigm shift in primary prevention.: "Are we losing the battle against cardiometabolic disease? The case for a paradigm shift in primary prevention
Lutz E Kraushaar and Alexander Krämer"

Preventing type 2 diabetes: can we make the evidence work? -- Yates et al. 85 (1007): 475 -- Postgraduate Medical Journal

Preventing type 2 diabetes: can we make the evidence work? -- Yates et al. 85 (1007): 475 -- Postgraduate Medical Journal: "Review
Preventing type 2 diabetes: can we make the evidence work?
T Yates1, M Davies1, K Khunti2"

Increases in Waist Circumference and Weight May Predict Incident Diabetes

Increases in Waist Circumference and Weight May Predict Incident Diabetes: "Increases in Waist Circumference and Weight May Predict Incident Diabetes CME"

Defining and Characterizing the Progression of Type 2 Diabetes — Diabetes Care

Defining and Characterizing the Progression of Type 2 Diabetes — Diabetes Care: "Defining and Characterizing the Progression of Type 2 Diabetes"

Defining and Characterizing the Progression of Type 2 Diabetes — Diabetes Care

Defining and Characterizing the Progression of Type 2 Diabetes — Diabetes Care: "Defining and Characterizing the Progression of Type 2 Diabetes
Vivian A. Fonseca, MD"

fulltext

PREVENCIA DIABETES MELLITUS 2. TYPU

SAMEDI: "Interná medicína 2009 / 4
PREVENCIA DIABETES MELLITUS 2. TYPU
Vladimír Uličiansky, Zbynek Schroner"


Interná medicína 2009 / 4
PREVENCIA DIABETES MELLITUS 2. TYPU
Vladimír Uličiansky, Zbynek Schroner

Diabetes mellitus (DM) predstavuje skupinu metabolických ochorení, ktoré sú charakterizované hyperglykémiou. Hyperglykémia je následkom poruchy sekrécie inzulínu a/alebo účinku inzulínu. DM 2. typu má výraznú genetickú zložku. Ochorenie je polygénne a multifaktoriálne. Faktory vonkajšieho prostredia (obezita, výživa, fyzická aktivita) na základe genetickej náchylnosti modulujú fenotyp.V rámci projektu „Prevalencia diabetes mellitus na Slovensku“ Mokáň a kol. zistili 7,0 % prevalenciu diabetes mellitus (DM), pričom v 5,3 % išlo o známy DM, 1,2 % novozistený DM podľa kritérií Americkej diabetologickej asociácie (ADA) a 0,5 % o ďalšie nové prípady DM po vykonaní orálneho glukózo-tolerančného testu (oGTT) u respondentov s potvrdenou hraničnou glykémiou nalačno. Plán Medzinárodnej diabetickej federácie (IDF) pre prevenciu DM 2. typu je založený na kontrole modifikovateľných rizikových faktorov. Môže byť rozdelený do dvoch cieľových skupín: ľudia s vysokým rizikom vývoja DM 2. typu a celá populácia. IDF navrhuje 3-stupňový plán prevencie: 1. identifikácia tých, ktorí môžu byť vo vyššom riziku (dotazník na určenie rizika DM 2. typu, glykémia nalačno, orálny glukózo-tolerančný test), 2. určenie miery rizika a 3. intervencia na prevenciu DM 2. typu (úprava životného štýlu, hmotnosť, fyzická aktivita, farmakologická intervencia). Plán IDF je veľmi podobný odporúčaniam Americkej diabetologickej asociácie a Slovenskej diabetologickej spoločnosti. Kľúčové slová: diabetes mellitus 2. typu - prevencia - životný štýl - metformín

PREVENTION OF TYPE 2 DIABETES MELLITUS

Diabetes mellitus (DM) is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Type 2 DM has a strong genetic component. The disease is polygenic and multifactorial since in addition to genetic susceptibility, enviromental factors (obesity, nutrition and physical activity) modulate the phenotype. In the project „Prevalence of diabetes mellitus in Slovakia“ Mokan et al. confirmed 7.0 % prevalence of diabetes mellitus, including 5.3 % of known DM, 1.2 % of new DM according to ADA criteria and 0.5 % of additional new cases of DM after oGTT in respondents with impaired fasting glucose. The plan of International Diabetes Federation (IDF) on Type 2 DM prevention is based on controlling modifiable risk factors and can be divided in two target groups: people at high risk of developing Type 2 DM and the entire population.The IDF proposes a three-step plan for the prevention: 1. indentification of those who may be at higher risk (type 2 diabetes risk assessment form, fasting plasma glucose, oral glucose tolerance test), 2. measurement of risk and 3. intervention to prevent the development of Type 2 DM (lifestyle changes, weight, physical activity, pharmacological intervention). Plan IDF is very similar to the recommendations of The American Diabetes Association and The Slovakian Diabetes Society. Key words: Type 2 Diabetes Mellitus - prevention - lifestyle - metformin

Interná med. 2009; 9(4): 181-187

CODHy: Debate Rages on HbA1c for Diabetes Diagnosis - in Meeting Coverage, CODHy from MedPage Today

Medical News: CODHy: Debate Rages on HbA1c for Diabetes Diagnosis - in Meeting Coverage, CODHy from MedPage Today: "CODHy: Debate Rages on HbA1c for Diabetes Diagnosis"

center for evidence based medicine

CEBM > Home: "Welcome to CEBM
Welcome to the web site of the Centre for Evidence-Based Medicine in Oxford in the UK.

Our broad aim is to develop, teach and promote evidence-based health care and provide support and resources to doctors and health care professionals to help maintain the highest standards of medicine.
Learn more about EBM and the CEBM."

Prediction of Type 1 Diabetes in the General Population — Diabetes Care

Prediction of Type 1 Diabetes in the General Population — Diabetes Care: "Prediction of Type 1 Diabetes in the General Population"

Real-Time Hypoglycemia Prediction Suite Using Continuous Glucose Monitoring — Diabetes Care

Real-Time Hypoglycemia Prediction Suite Using Continuous Glucose Monitoring — Diabetes Care: "Real-Time Hypoglycemia Prediction Suite Using Continuous Glucose Monitoring
A safety net for the artificial pancreas"

TULIP - Tubingen lifestyle intervention program

Ziele: DIABETES PREVENTION
METABOLIC, VASCULAR, FUNCTIONAL STUDIES


"Hintergrund
Der Alterszucker (Diabetes mellitus Typ 2) hat in den vergangen Jahren dramatisch zugenommen. In Deutschland sind etwa 6% der Erwachsenen betroffen, d.h. mehr als 4 Mio. Menschen. Wir gehen davon aus, daß im Jahr 2010 diese Zahl 8 Mio. erreichen wird. Diese Zunahme der Erkrankungshäufigkeit (die nur von AIDS in einigen afrikanischen Ländern übertroffen wird) hängt mit unserem modernen Lebenstil zusammen: mehr sitzende Berufe und weniger körperliche Bewegung, sowie leichter Zugang zu zuviel kalorienreichen Nahrungsmitteln. Das heimtückische am Diabetes sind die früh und schleichend beginnenden Gefäßschäden."

Atorvastatin Causes Insulin Resistance and Increases Ambient Glycemia in Hypercholesterolemic Patients -- Koh et al. 55 (12): 1209 -- Journal of the American College of Cardiology

Atorvastatin Causes Insulin Resistance and Increases Ambient Glycemia in Hypercholesterolemic Patients -- Koh et al. 55 (12): 1209 -- Journal of the American College of Cardiology: "Atorvastatin Causes Insulin Resistance and Increases Ambient Glycemia in Hypercholesterolemic Patients
Kwang Kon Koh,"

family HEALTHWARE - family history screening tool XX

Cited by ..: "Developing Family Healthware, a Family History Screening Tool to Prevent Common Chronic Diseases
Paula W. Yoon, Maren T. Scheuner, Cynthia Jorgensen, and Muin J. Khoury
Prev Chronic Dis. 2009 January; 6(1): A33. Published online 2008 December 15.
PMCID: PMC2644613"

Cited by ..

Cited by ..: "Common Genetic Variation in Candidate Genes and Susceptibility to Sub-types of Breast Cancer
Nasim Mavaddat, Alison M Dunning, Bruce AJ Ponder, Douglas F Easton, and Paul D Pharoah
Cancer Epidemiol Biomarkers Prev. Author manuscript; available in PMC 2009 July 1.
PMCID: PMC2655077
Published in final edited form as: Cancer Epidemiol Biomarkers Prev. 2009 January; 18(1): 255–259. doi: 10.1158/1055-9965.EPI-08-0704."

A constant risk for familial breast cancer?

Cited by ..: "A constant risk for familial breast cancer? A population-based family study
Kamila Czene, Marie Reilly, Per Hall, and Mikael Hartman
Breast Cancer Res. 2009; 11(3): R30. Published online 2009 May 20. doi: 10.1186/bcr2260.
PMCID: PMC2716498"

Familial breast cancer: collaborative reanalysis o... [Lancet. 2001] - PubMed result

Familial breast cancer: collaborative reanalysis o... [Lancet. 2001] - PubMed result: "Familial breast cancer: collaborative reanalysis of individual data from 52 epidemiological studies including 58,209 women with breast cancer and 101,986 women without the disease.
Collaborative Group on Hormonal Factors in Breast Cancer."

Population-based family history-specific risks for... [Gastroenterology. 2010] - PubMed result

Population-based family history-specific risks for... [Gastroenterology. 2010] - PubMed result: "Population-based family history-specific risks for colorectal cancer: a constellation approach.
Taylor DP, Burt RW, Williams MS, Haug PJ, Cannon-Albright LA."

Population-based family history-specific risks for... [Gastroenterology. 2010] - PubMed result

Population-based family history-specific risks for... [Gastroenterology. 2010] - PubMed result: "Population-based family history-specific risks for colorectal cancer: a constellation approach.
Taylor DP, Burt RW, Williams MS, Haug PJ, Cannon-Albright LA."

http://www.ncbi.nlm.nih.gov/pubmed?term=Machicao_F


Pubmed

disposition index, insulin secretion adjusted for ambient insulin sensitivity

disposition index - stumvoll 2005 - pdf

Bergmann 2007 DIABETES : Orchestration of Glucose Homeostasis

Current approaches for assessing insulin sensitivity and resistance in vivo: advantages, limitations, and appropriate usage //2008 // Muniyappa et al. 294 (1): E15. (2008) /// ***** VERY USEFUL OVERVIEW


recent thought provoking article
FAERCH 2010
DISPOSITION INDEX * insulin sensitivity - peripheral vs hepatic
Abstract
The assessment of pancreatic β cell function in humans is challenging because of a complex interplay between insulin secretion, insulin sensitivity and hepatic insulin extraction. Simplified, the relationship between insulin secretion and insulin sensitivity can be described by an approximate hyperbola with the product of the two variables being constant for individuals with the same degree of glucose tolerance (the disposition index). Strengths and limitations of the disposition index have been widely debated in the literature. In this review we will focus on another and until recently unrecognized dimension of the disposition index, namely the issue of adjusting insulin secretion for hepatic versus peripheral insulin sensitivity. An underlying assumption of this issue is that the liver as compared to muscle plays a different role in the regulation of in vivo insulin secretion